Logo
Perfectha SubSkin without Lidocaine

Perfectha SubSkin without Lidocaine

Perfectha

Dermal Fillers
  • CE Marked Class III medical device in the EU/EEA for intradermal/subcutaneous injection.
Deep Volumising Hyaluronic Acid Filler (Subcutaneous / Supra-periosteal)

Description

Perfectha SubSkin without Lidocaine is a deeply volumising, cross-linked hyaluronic acid dermal filler from Sinclair’s Perfectha range. Formulated at 20 mg/ml with large gel particles (~2,000 particles/ml), it is intended for subcutaneous to supra-periosteal injection to redefine facial contours, augment cheeks, chin and jawline, correct significant volume loss, and rejuvenate ageing hands. Supplied as 3 x 1 ml prefilled syringes (total 3 ml), this non-lidocaine version uses highly pure, non-animal HA and offers long-lasting results of approximately 12–18 months when administered by trained medical professionals.

Bnefits

  • Redefines facial contours and restores volume in malar areas, cheeks, chin and jawline for a more sculpted appearance.
  • Effectively treats pronounced volume loss, severe skin depressions and deep tissue scarring, as well as age-related asymmetry and facial lipoatrophy.
  • Provides hand rejuvenation by restoring volume and masking tendons and veins for a more youthful look.
  • High cross-linking rate (~90%) and large particle size (2,000 gel particles/ml) ensure stability, strong lifting capacity and long duration (12–18 months).
  • Non-animal origin, biphasic HA with undetectable/very low BDDE levels contributes to a favourable safety profile.
  • Immediate visible results, with natural-looking volume and contour enhancement.
  • Formulation without lidocaine offers an option for patients who prefer or require filler without local anaesthetic, while allowing practitioners to tailor anaesthesia separately.

Indications

  • Redefining and augmenting facial contours (cheekbones/malar region, chin, jawline).
  • Volume restoration in cheeks, temples, and midface for age-related volume loss or lipoatrophy.
  • Treatment of deep wrinkles and folds including nasolabial and mentolabial folds and pronounced marionette lines.
  • Correction of significant skin depressions and deep tissue scarring.
  • Non-surgical reshaping of nose bridge (non-surgical rhinoplasty) in selected cases.
  • Hand rejuvenation by restoring dorsal hand volume.

Composition

  • Stabilised, cross-linked, non-animal hyaluronic acid 20 mg/ml (20 g/L).
  • Biphasic HA gel with approximately 2,000 gel particles/ml and cross-linking rate around 90%.
  • Phosphate-buffered saline, pH ~7.
  • Undetectable or very low levels of cross-linking agent BDDE (per manufacturer technical description).
  • Does not contain lidocaine or other local anaesthetic agents.

Formulation

  • Highly cross-linked, large-particle, biphasic hyaluronic acid gel for deep volumisation.
  • Injectable, resorbable filler for subcutaneous to supra-periosteal administration using needle or cannula.
  • Sterile, pyrogen-free, non-animal HA derived via biofermentation.

Packaging

  • Three (3) prefilled glass syringes each containing 1 ml of Perfectha SubSkin gel (total 3 ml).
  • Typically supplied with 1 x 21G cannula and 1 x 21G needle (or equivalent) and multiple traceability labels.
  • Delivered in original manufacturer box with product leaflet and IFU, sealed for professional use.

Usage

  • For use only by appropriately trained and qualified medical professionals with expertise in facial anatomy and dermal filler techniques.
  • Cleanse and disinfect the treatment area; ensure aseptic technique throughout the procedure.
  • Inject Perfectha SubSkin into the deep subcutaneous or supra-periosteal plane using a needle or blunt cannula, depending on area and technique.
  • Recommended techniques include bolus, linear threading and fanning retro-injection; inject slowly with cannula orifice facing upwards while withdrawing.
  • Avoid overcorrection; gently massage treated areas to distribute the gel and correct minor irregularities. If blanching occurs, massage until normal colour returns.
  • Do not inject into inflamed, infected, diseased or previously over-filled areas and strictly avoid intravascular injection.
  • After treatment, advise patients to avoid makeup for 24 hours and limit intense UV exposure, saunas, extreme cold or vigorous exercise for several days.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid or any component of the filler.
  • History of severe allergic reactions or anaphylaxis.
  • Active skin infection, inflammation or disease in or near the intended injection site (e.g., acne, herpes, dermatitis).
  • Autoimmune diseases or immunosuppression unless thoroughly assessed and approved by the treating physician.
  • Pregnancy or breastfeeding, in line with common aesthetic-medicine precautions (lack of safety data).
  • Bleeding disorders or ongoing anticoagulant/antiplatelet therapy where the risk has not been appropriately evaluated.
  • Previous permanent fillers or foreign bodies in the same area, unless considered safe by an experienced practitioner.

Adverse Effects

  • Common, transient reactions: erythema, swelling, pain, tenderness, bruising or itching at injection sites.
  • Possible papules, nodules or palpable lumps if product is unevenly distributed or injected too superficially.
  • Less common events: local infection, prolonged oedema, inflammatory reactions or delayed hypersensitivity.
  • Rare but serious complications: vascular occlusion (with risk of tissue necrosis), embolic events or visual disturbances if injected intravascularly; these require urgent recognition and management with hyaluronidase and appropriate medical care.

Storage Conditions

  • Store in a cool, dry place away from direct sunlight at 2–30 °C (or 2–25 °C, per local labelling).
  • Do not freeze; avoid exposure to excessive heat.
  • Keep syringes in their original blister and carton until immediately prior to use.
  • Store out of reach of children and unauthorised persons; discard any opened, unused product according to clinical waste regulations.

Duration

Clinical and real-world data indicate a longevity of approximately 12\u201318 months for Perfectha SubSkin, depending on area treated, patient metabolism, lifestyle and injection technique.

Onset

Volume restoration and contouring effects are typically visible immediately after injection, with final integration and refinement over the following days to weeks.

Browse more Dermal Fillers

Top Treatments

Top Cities in the UK